Yifan Xinfu Pharmaceutical Co Ltd
Yifan Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products, raw materials, and polymer materials in Southeast Asia, Europe and North America, Singapore, South Korea, Italy, China, Germany, and the United States. It offers Chinese patent medicines, chemical medicines and biological medicines; and vitamin products, including vitamin B5 an… Read more
Yifan Xinfu Pharmaceutical Co Ltd (002019) - Total Liabilities
Latest total liabilities as of September 2025: CN¥4.40 Billion CNY
Based on the latest financial reports, Yifan Xinfu Pharmaceutical Co Ltd (002019) has total liabilities worth CN¥4.40 Billion CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Yifan Xinfu Pharmaceutical Co Ltd - Total Liabilities Trend (2001–2024)
This chart illustrates how Yifan Xinfu Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Yifan Xinfu Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Yifan Xinfu Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Aarti Industries Limited
NSE:AARTIIND
|
India | ₹59.90 Billion |
|
Grupo Gigante S. A. B. de C. V
PINK:GPGNF
|
USA | $27.14 Billion |
|
Partner Communications Company Ltd.
PINK:PTNRF
|
USA | $2.36 Billion |
|
Universal Robina Corporation
PINK:UVRBF
|
USA | $58.05 Billion |
|
Vizio Holding Corp
NYSE:VZIO
|
USA | $508.60 Million |
|
Alliance Financial Group Bhd
KLSE:2488
|
Malaysia | RM77.88 Billion |
|
Shenzhen United Winners Laser Co Ltd
SHG:688518
|
China | CN¥4.62 Billion |
Liability Composition Analysis (2001–2024)
This chart breaks down Yifan Xinfu Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.27 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.50 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.34 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Yifan Xinfu Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Yifan Xinfu Pharmaceutical Co Ltd (2001–2024)
The table below shows the annual total liabilities of Yifan Xinfu Pharmaceutical Co Ltd from 2001 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥3.86 Billion | +18.93% |
| 2023-12-31 | CN¥3.24 Billion | -4.49% |
| 2022-12-31 | CN¥3.40 Billion | +0.20% |
| 2021-12-31 | CN¥3.39 Billion | +16.63% |
| 2020-12-31 | CN¥2.91 Billion | -10.39% |
| 2019-12-31 | CN¥3.24 Billion | +12.36% |
| 2018-12-31 | CN¥2.89 Billion | +45.42% |
| 2017-12-31 | CN¥1.99 Billion | -35.60% |
| 2016-12-31 | CN¥3.08 Billion | +85.03% |
| 2015-12-31 | CN¥1.67 Billion | +110.58% |
| 2014-12-31 | CN¥791.21 Million | +42.99% |
| 2013-12-31 | CN¥553.34 Million | -4.72% |
| 2012-12-31 | CN¥580.73 Million | -16.65% |
| 2011-12-31 | CN¥696.73 Million | +39.97% |
| 2010-12-31 | CN¥497.79 Million | +118.99% |
| 2009-12-31 | CN¥227.31 Million | -20.35% |
| 2008-12-31 | CN¥285.39 Million | -15.03% |
| 2007-12-31 | CN¥335.87 Million | +25.36% |
| 2006-12-31 | CN¥267.92 Million | +36.68% |
| 2005-12-31 | CN¥196.02 Million | +302.32% |
| 2004-12-31 | CN¥48.72 Million | -53.48% |
| 2003-12-31 | CN¥104.73 Million | +99.37% |
| 2002-12-31 | CN¥52.53 Million | +49.85% |
| 2001-12-31 | CN¥35.05 Million | -- |